The Role of Urologists in the Management of Hormone-Refractory Prostate Cancer

Carter, 1990, The prostate: An increasing medical problem, Prostate, 16, 39, 10.1002/pros.2990160105 Smith, 1998, Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer, J. Clin. Oncol., 16, 1835, 10.1200/JCO.1998.16.5.1835 Eisenberger MA. Chemotherapy in prostate cancer. In: Crawford ED, Das S, editors. Current Genitourinary Cancer Surgery. Philadelphia (PA): Lea & Febiger, 1990. p. 507–518. Eisenberger, 1985, A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic cacinoma, J. Clin. Oncol., 3, 827, 10.1200/JCO.1985.3.6.827 Yagoda, 1993, Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer, Cancer, 71, 1098, 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G Dawson, 1999, Response criteria in prostatic carcinoma, Semin. Oncol., 26, 174 Bubley, 1999, Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group, J. Clin. Oncol., 17, 3461, 10.1200/JCO.1999.17.11.3461 Kreis, 1997, Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines, Br. J. Urol., 79, 196, 10.1046/j.1464-410X.1997.06310.x Hudes, 1992, Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer, J. Clin. Oncol., 10, 1754, 10.1200/JCO.1992.10.11.1754 Pienta, 1994, Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate, J. Clin. Oncol., 12, 2005, 10.1200/JCO.1994.12.10.2005 Hudes, 1997, J. Clin. Oncol., 15, 3156, 10.1200/JCO.1997.15.9.3156 Petrylak, 1999, Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer, J. Clin. Oncol., 17, 958, 10.1200/JCO.1999.17.3.958 Smith, 1999, Complications of advanced prostate cancer, Urology, 54, 8, 10.1016/S0090-4295(99)00448-3 Benson, 1982, External beam radiotherapy for palliation of pain from metastatic carcinoma of the prostate, J. Urol., 127, 69, 10.1016/S0022-5347(17)53609-5 Epstein, 1979, Half and total body radiation for carcinoma of the prostate, J. Urol., 122, 330, 10.1016/S0022-5347(17)56391-0 Ben-Josef, 1997, Radioisotopes in the treatment of bone metastases, Ann. Med., 29, 31, 10.3109/07853899708998741 Eisenberg, 1998, Trends in alternative medicine use in the United States, 1990–1997: Results of a follow-up national survey, JAMA, 280, 1569, 10.1001/jama.280.18.1569 Lissoni, 1997, Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by pineal hormone melatonin, efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone, Eur. Urol., 31, 178, 10.1159/000474446 Reichlin, 1993, Neuroendocrine-immune interactions, New Engl. J. Med., 329, 1246, 10.1056/NEJM199310213291708